Evidence map›Paper›PMID 37373182›Full record

ArticleInternational journal of molecular sciences2023

Ubiquitination of GRK2 Is Required for the β-Arrestin-Biased Signaling Pathway of Dopamine D2 Receptors to Activate ERK Kinases.

Haiping Liu, Haixiang Ma, Xingyue Zeng, Chengyan Wu, Srijan Acharya, Sarabjeet Kour Sudan, Xiaohan Zhang

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. The roles of G protein-coupled receptor kinase 2 in renal diseases.Journal of cellular and molecular medicine · 2024
    Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Haiping LiuSchool of Pharmaceutical Sciences, Guizhou University, Guiyang 550025, China.
Haixiang MaSchool of Pharmaceutical Sciences, Guizhou University, Guiyang 550025, China.
Xingyue ZengSchool of Pharmaceutical Sciences, Guizhou University, Guiyang 550025, China.
Chengyan WuSchool of Pharmaceutical Sciences, Guizhou University, Guiyang 550025, China.
Srijan AcharyaMitchell Cancer Institute, School of Medicine, University of South Alabama, Mobile, AL 36604, USA.
Sarabjeet Kour SudanMitchell Cancer Institute, School of Medicine, University of South Alabama, Mobile, AL 36604, USA.
Xiaohan ZhangSchool of Pharmaceutical Sciences, Guizhou University, Guiyang 550025, China.
Guizhou University · CNUniversity of South Alabama · USUSA Mitchell Cancer Institute · US

Funding

Education Office of Guizhou KY[2021]085Guizhou University [2020]07 and [2019]66National Natural Science Foundation of China 82060263Science and Technology Foundation of Guizhou [2020]1Y084
6 · The paper itself

Abstract

A class-A GPCR dopamine D2 receptor (D2R) plays a critical role in the proper functioning of neuronal circuits through the downstream activation of both G-protein- and β-arrestin-dependent signaling pathways. Understanding the signaling pathways downstream of D2R is critical for developing effective therapies with which to treat dopamine (DA)-related disorders such as Parkinson's disease and schizophrenia. Extensive studies have focused on the regulation of D2R-mediated extracellular-signal-regulated kinase (ERK) 1/2 signaling; however, the manner in which ERKs are activated upon the stimulation of a specific signaling pathway of D2R remains unclear. The present study conducted a variety of experimental techniques, including loss-of-function experiments, site-directed mutagenesis, and the determination of protein interactions, in order to investigate the mechanisms underlying β-arrestin-biased signaling-pathway-mediated ERK activation. We found that the stimulation of the D2R β-arrestin signaling pathway caused Mdm2, an E3 ubiquitin ligase, to move from the nucleus to the cytoplasm and interact with tyrosine phosphorylated G-protein-coupled receptor kinase 2 (GRK2), which was facilitated by Src, a non-receptor tyrosine kinase. This interaction led to the ubiquitination of GRK2, which then moved to the plasma membrane and interacted with activated D2R, followed by the phosphorylation of D2R as well as the mediation of ERK activation. In conclusion, Mdm2-mediated GRK2 ubiquitination, which is selectively triggered by the stimulation of the D2R β-arrestin signaling pathway, is necessary for GRK2 membrane translocation and its interaction with D2R, which in turn mediates downstream ERK signaling. This study is primarily novel and provides essential information with which to better understand the detailed mechanisms of D2R-dependent signaling.

Indexed as

G-Protein-Coupled Receptor Kinase 2Signal Transductionbeta-Arrestin 1beta-ArrestinsDopaminePhosphorylationReceptors, Dopamine D2Ubiquitinationbeta-Arrestin 1beta-ArrestinsDopamineG-Protein-Coupled Receptor Kinase 2Receptors, Dopamine D2D2R-biased signalingERK signalingGRK2 ubiquitinationSrc

Identifiers

PMID37373182
PMCPMC10298151
OpenAlexW4380486450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.